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Startle diseaseStartle disease is a rare, potentially fatal neuromotor disorder characterized by exaggerated startle reﬂexes
and hypertonia in response to sudden unexpected auditory, visual or tactile stimuli. Mutations in the GlyR
α1 subunit gene (GLRA1) are the major cause of this disorder, since remarkably few individuals with muta-
tions in the GlyR β subunit gene (GLRB) have been found to date. Systematic DNA sequencing of GLRB in in-
dividuals with hyperekplexia revealed new missense mutations in GLRB, resulting in M177R, L285R and
W310C substitutions. The recessive mutation M177R results in the insertion of a positively-charged residue
into a hydrophobic pocket in the extracellular domain, resulting in an increased EC50 and decreased maximal
responses ofα1β GlyRs. The de novomutation L285R results in the insertion of a positively-charged side chain
into the pore-lining 9′ position. Mutations at this site are known to destabilize the channel closed state and
produce spontaneously active channels. Consistent with this, we identiﬁed a leak conductance associated
with spontaneous GlyR activity in cells expressing α1βL285R GlyRs. Peak currents were also reduced for
α1βL285R GlyRs although glycine sensitivity was normal. W310C was predicted to interfere with hydrophobic
side-chain stacking between M1, M2 and M3. We found that W310C had no effect on glycine sensitivity, but
reduced maximal currents in α1β GlyRs in both homozygous (α1βW310C) and heterozygous (α1ββW310C)
stoichiometries. Since mild startle symptoms were reported in W310C carriers, this may represent an exam-
ple of incomplete dominance in startle disease, providing a potential genetic explanation for the ‘minor’ form
of hyperekplexia.
© 2012 Elsevier Inc.Open access under CC BY license. Introduction
Inhibitory glycine receptors (GlyRs) are ligand-gated chloride
channels enriched in the spinal cord, brainstem and retina, consisting
of heteropentameric combinations of ligand-binding GlyR α subunits
(α1–α4) together with the GlyR β subunit (Lynch, 2009). Each GlyR
subunit is composed of an N-terminal extracellular domain and four
α-helical membrane-spanning domains (M1–M4). M3 and M4 areogy, UCL School of Pharmacy,
ngdom.
irect.com).
license. linked by a long intracellular domain containing binding sites for a
variety of intracellular factors. Although GlyR α and β subunits both
play an active role in agonist binding (Dutertre et al., 2012;
Grudzinska et al., 2005), the GlyR β subunit was, until recently, wide-
ly assumed to play solely a structural role in heteromeric GlyRs. In
part, this was due to the key role of the GlyR β subunit in mediating
high-afﬁnity interactions with the synaptic clustering molecule
gephyrin (Meyer et al., 1995), which in turn controls the dynamic lo-
calization of GlyRs at synaptic sites (Feng et al., 1998). More recently,
the GlyR β subunit was also reported to interact with the proteins
Vacuolar Protein Sorting 35 (Vps35) and Neurobeachin (Nbea), indi-
cating a new role in GlyR trafﬁcking (del Pino et al., 2011). However,
the atypical M2 domain of the GlyR β subunit also confers resistance
to the effects of picrotoxinin (Pribilla et al., 1994) and the insecticide
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single-channel conductances of heteromeric αβ GlyRs (Bormann et
al., 1993).
Initial cross-linking studies of afﬁnity-puriﬁed nativeGlyRs suggested
that heteromeric GlyRs exist in a 3α:2β subunit combination (Langosch
et al., 1988). However, three innovative studies have recently revealed
that the GlyRβ subunit represents themajor component of heteromeric
GlyRs, which are more likely to exist in a 2α:3β stoichiometry.
Grudzinska et al., 2005 compared the effects of mutations affecting
predicted glycine binding residues in GlyR α1 and β subunits. Co-
expression of mutant GlyR α1 with wild-type β subunits resulted in a
full rescue of the EC50 value for glycine, whilst co-expression of
wild-type GlyR α1 with mutant β subunits resulted in a decrease in
EC50. A subsequent study (Dutertre et al., 2012) revealed that the GlyR
β subunit contributes more to agonist binding site formation than
had been previously realized. Experiments with GlyR α1-β subunit
concatemers also revealed that functional heteromeric GlyRs can be
produced when these were co-expressed with GlyR β subunit mono-
mers but notwhen expressed alone, orwithGlyRα1 subunitmonomers
(Grudzinska et al., 2005). This result was consistentwith either a 2α:3β
or a 1α:4β stoichiometry. However, quantiﬁcation of (35S)methionine
incorporation into recombinantα1β versusα1 subunit GlyRs suggested
a 2α:3β stoichiometry and the subunit order β-α-β-α-β. This stoichi-
ometry and subunit arrangement has recently been conﬁrmed by imag-
ing single antibody-bound GlyR α1β heteromers using atomic force
microscopy (Yang et al., 2012).
Defects in the adult GlyR isoform (α1β) also have an important
role in disease. Mutations in GLRA1, encoding the GlyR α1 subunit,
are the major genetic cause of startle disease/hyperekplexia in
humans (Chung et al., 2010; Shiang et al., 1993, 1995) and cause sim-
ilar disorders in mice (Buckwalter et al., 1994; Holland et al., 2006;
Ryan et al., 1994; Traka et al., 2006) and Poll Hereford cattle (Pierce
et al., 2001). In humans, hyperekplexia affects newborn children
and is characterized by exaggerated startle reﬂexes and hypertonia
in response to sudden, unexpected auditory, tactile or visual stimuli.
By contrast, GLRB mutations are less frequent, but recessive muta-
tions have been discovered in three families with hyperekplexia
(Al-Owain et al., 2012; Lee et al., 2012; Rees et al., 2002), in the
mouse mutant spastic (Kingsmore et al., 1994; Mülhardt et al.,
1994) and the zebraﬁsh bandoneonmutant (Hirata et al., 2005). How-
ever, one conundrum is why so few GLRB mutations are found in
startle disease relative to GLRA1, or SLC6A5, encoding the presynaptic
glycine transporter GlyT2, which are the primary and secondary
genetic causes of startle disease respectively (Carta et al., 2012;
Giménez et al., 2012; Rees et al., 2006). Here we report the character-
ization of three new missense mutations in GLRB, resulting in M177R,
L285R and W310C substitutions in the extracellular domain, and the
M2 and M3 membrane-spanning domains, respectively. We present
detailed molecular modeling and functional analysis of these new
GlyR β subunit mutations, revealing novel pathogenic mechanisms
and modes of inheritance.Materials and methods
Patients and cases
49 individuals with a clinical diagnosis of hyperekplexia (non-
habituating startle response, positive nose tap test, history of neonatal/
infantile hypertonicity) but lacking mutations in GLRA1 and SLC6A5
were ascertained by referral from pediatricians from international
centers. DNA analysis of GLRBwas performed at the Laboratory for Diag-
nostic Genome Analysis (LDGA) of the Center of Human and Clinical Ge-
netics of the Leiden University Medical Center. The LDGA is NEN-EN-ISO
15189:2007 accredited by the Dutch Accreditation Council. Informed
consent for participation in the study and publication of clinical andgenetic data was obtained by the referring clinicians (MV at Sahlgrenska
University Hospital and FMC at Imperial College London).Genetic analysis
DNA was extracted from whole blood taken from affected individ-
uals and relatives using a Gentra Puregene DNA puriﬁcation Kit (Gentra
Systems, Minneapolis, USA). Primers recognizing the ten GLRB coding
exons and ﬂanking splice sites were designed using the Lightscanner
Primer Design Software package, version 1 (Idaho Technology Inc, Salt
Lake City, Utah). To avoid allelic dropout, all primers were placed in
intronic regions that were devoid of single-nucleotide polymorphisms
(SNPs) as revealed by National Center for Biotechnology Information
databases. Primer designs are provided in Supplementary table 1. Am-
pliﬁed PCR fragments were sequenced on an ABI PRISM 3730 using
the BigDye Terminator cycle sequencing ready reaction kit (Applied
Biosystems, Foster City, CA, USA) and analyzed using SeqScap software
for comparative sequence analysis (Applied Biosystems). Single nucleo-
tide variants (SNVs) were assessed against those found in NCBI dbSNP
Build 136 and release 20100804 from the 1000 genomes project.Homology modeling of the human GlyR
Fold recognition of human GlyR α1 and β subunits was performed
with HHPred (Söding et al., 2005), identifying the structure of the
Caenorhabditis elegans glutamate-gated chloride channel (GluCl;
PDB: 3RHW) (Hibbs and Gouaux, 2011) as the best template
(p-value: 0). A proﬁle–proﬁle alignment between the human GlyR
α1 subunit and the GluCl α subunit was generated using MUSCLE
(Edgar, 2004) and T-COFFEE (Notredame et al., 2000) resulting in
44.4% sequence identity. A separate alignment was generated for
the human GlyR β subunit and GluCl resulting in 38.9% sequence
identity. A short part of the sequence at the N-terminus of the β
subunit (residues 1–30), and the extended loop region between M3
and M4 of both the α1 and β subunits (residues 312–396 and
337–453, respectively) could not be accurately modeled due to lack
of sequence identity and were therefore removed. The two align-
ments were inspected manually and combined to include all ﬁve sub-
units together to re-create the entire pentameric structure in the
stoichiometry 2α1:3β with the subunit arrangement β-α-β-α-β.
Using MODELLER-9v10 (Eswar et al., 2003), 50 models were built
based on the combined alignment, restraining disulﬁde bonds between
the cysteine residues involved in the cys-loops within each subunit
(C138–C152 and C198–C209 in the α1 subunit and C161–C175 and
C221–C233 in the β subunit). Each model was assessed by MODELLER
with the Discrete Optimized Protein Energy (DOPE) statistical potential
score (Shen and Sali, 2006) and the optimal model was selected based
on the lowest score (normalized DOPE Z score: −0.222). A further
assessment of model quality was performed using QMEAN (Benkert
et al., 2011) The QMEAN Z score for the human GlyR α1β model was
−3.43, indicating a reasonable model (Benkert et al., 2011). Selected
non-synonymous substitutions were modeled into the GlyR homology
model with the swapaa command in Chimera (Pettersen et al., 2004)
using the Dunbrack backbone-dependent rotamer library (Dunbrack,
2002) and taking into account the lowest clash score, highest number
of H-bonds and highest rotamer probability.Site-directed mutagenesis and expression constructs
Full-length human GlyR α1 and β subunits were cloned into the
vector pRK5 as previously described (Chung et al., 2010). Mutations
were introduced into pRK5-hGlyRβ using the QuikChange site-
directed mutagenesis kit (Agilent). All expression constructs were
conﬁrmed by Sanger sequencing of the entire coding region.
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Wild-type or mutant GlyR α1β heteromers were transiently-
expressed in human embryonic kidney (HEK293) cells transfected
using magnetofection (CombiMag: OZ Biosciences, Lipofectamine
2000; Invitrogen). GlyR α1 and β subunit expression constructs were
transfected at a DNA ratio of 1:10 to promote the formation of
heteromeric α1β GlyRs. 32 h after transfection, cell surface-expression
of GlyR β subunits was measured using a cell membrane-impermeable
reagent Sulfo-NHS-LC-Biotin (Pierce Biotechnology) as previously de-
scribed (Chung et al., 2010). Proteins in the whole-cell lysates or
cell-surface proteins were analyzed by Western blotting with an anti-
body against the GlyR β subunit (1:90; AbCam ab123886). An anti
β-actin antibody (1:5000; AbCam) was used as a control to conﬁrm
that intracellular proteins were not labeled with biotin. The intensity
of the immunoreactivity signal was quantiﬁed using ImageJ (http://
rsbweb.nih.gov/ij/).
Fluorescence-based imaging
Cells were imaged using an automated ﬂuorescence-based screen-
ing system using EYFPI152L ﬂuorescence quench as an indicator of
anion inﬂux. In this technique, iodide ﬂowing into the cell binds to
and quenches EYFPI152L ﬂuorescence, thus providing an indication of
the relative activity levels of membrane anion channels (Kruger et
al., 2005). Brieﬂy, HEK AD293 cells were transfected with the plasmid
DNAs for wild-type and mutant GlyRs and with the DNA for EYFPI152L
as described in the results and plated into a 384-well plate. Unless
otherwise indicated, all GlyR plasmid DNAs were transfected in equi-
molar ratios for both the ﬂuorescence and patch-clamp electrophysi-
ological assays. Within the following 24–32 h, the culture medium in
the wells was replaced with extracellular solution (140 mM NaCl,
5 mM KCl, 2 mM CaCl2, 1 mMMgCl2, 10 mM HEPES, and 10 mM glu-
cose, pH 7.4 using NaOH). After 30 min, ﬂuorescence images of each
well were obtained twice, before and after the application of NaI solu-
tion (140 mM NaI, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM
HEPES, and 10 mM glucose, pH 7.4 using NaOH) containing varying
concentrations of glycine. Values were pooled from 3 to 4 experi-
ments with three wells each containing >200 cells. To determine
the glycine dose–response curve, an empirical three or four parame-
ter Hill equation was ﬁtted by a non-linear least squares algorithm
using SigmaPlot 11.0 software. Throughout this study, ‘% quench’ is
deﬁned as the (initial ﬂuorescence−ﬁnal ﬂuorescence)×100/initial
ﬂuorescence. Thus, a treatment that completely abolished all ﬂuores-
cence would yield a 100% quench.
Electrophysiology
Glycine-gated currents were measured using whole-cell patch-
clamp electrophysiology at a holding potential of−40 mV. Spontane-
ous single-channel currents were recorded from outside-out excised
patches, held at −70 mV and in the absence of agonist. HEK AD293
cells were transiently transfected with GlyR subunit expression con-
structs and plated on coverslips. Cells were continually superfused
with extracellular solution (composition as above) and visualized
with an inverted ﬂuorescence microscope. Transfected cells were
identiﬁed by co-transfection with an EGFP expression construct.
Patch pipettes were pulled to ﬁnal tip resistances of 1–4 MΩ
(whole-cell) and 6–12 MΩ (outside-out) when ﬁlled with a standard
intracellular solution (145 mM CsCl, 2 mM CaCl2, 2 mM MgCl2,
10 mMHEPES, 10 mM EGTA, pH 7.4 with CsOH). Whole-cell currents,
which were ﬁltered at 1 kHz and digitized at 2 kHz, were recorded
using an Axon MultiClamp 700B ampliﬁer and pClamp10.2 software.
Single-channel currents, which were ﬁltered at 5 kHz and digitized
at 20 kHz, were recorded using an Axon Axopatch 200B and
pClamp10.2 software. Drugs diluted in extracellular solution wereapplied to cells or patches via gravity-forced perfusion using parallel
small tubes. Solution exchange was complete within 200 ms.
Results
Mutation analysis of GLRB in hyperekplexia
Individuals with startle disease lacking mutations in GLRA1 and
SLC6A5 were screened for genetic variation in GLRB coding exons
and donor and acceptor splice junctions by Sanger DNA sequencing.
Sequence variants were assigned as potentially pathogenic after
cross-referencing with known GLRB mutations and common GLRB
polymorphisms found in dbSNP and the 1000 genomes project. This
analysis revealed two novel sequence variants in GLRB (Fig. 1A, B,
Table 1) in two individuals. Individual 1 harbored a two base mis-
sense mutation (c.920_921ΔinsGA) resulting in a L285R substitution
in the second membrane-spanning domain (M2) of the GlyR β
subunit. Since this change was found in the heterozygous state
(Fig. 1A, B) and neither parent carries the mutation, this mutation ap-
pears to be de novo. By contrast, individual 2 harbored a different mis-
sense mutation (c.G996T), resulting in a W310C substitution in the
third membrane-spanning domain (M3) of the GlyR β subunit. At
ﬁrst glance, this mutation appeared to show recessive inheritance,
since both parents were heterozygous carriers. However, clinical as-
sessments and functional data suggest an alternative mechanism of
inheritance for this mutation (see below). Recently, another recessive
mutation c.T596G, resulting in a M177R substitution, was reported
(Al-Owain et al., 2012) in nine patients in a large family of Saudi
Arabian origin with hyperekplexia and esotropia, an eye misalignment
disorder where one or both eyes turn inward.
Clinical assessment
Individual 1 is a male of white British descent born at term plus
11 days. His weight and height were on the 3rd centile at delivery.
Apneas were observed within 40 min and hypertonia presented
within the ﬁrst hour after birth. These symptoms were severe enough
to necessitate intubation, his rigidity made ventilation very difﬁcult
and startle was prominent during this time. The classical nose-tap re-
ﬂex was also present. Magnetic resonance imaging (MRI) revealed
subtle brain abnormalities, including a mild increase in signal on
T2-weighted sequences in the white matter and obvious dentate
nuclei; however the basal ganglia had an unremarkable appearance.
At 3 months of age stereotyped but unusual dystonic posturing move-
ments were observed, including an arm-raising phenomenon that was
followed by a period of generalized hypertonia during which voluntary
movements were impossible. At 9 months, his gross motor perfor-
mance was at the level of 7 months. Although this had broadly normal-
ized by 14 months, dystonic movements were still prominent. Minor
motor delay remained a feature for some time and when last seen he
was still hypereﬂexic and had prominent cervical hypertonia, although
exaggerated startle was less prominent; he also had an alternating stra-
bismus. Now at 9 years, he remains small for his age. He still has very
mild motor delay, but stiffness is not noticeable and he plays football
regularly. He ismaking good progress in school and socially. He ismildly
myopic but no longer has strabismus. No epileptic seizures have been
observed.
Individual 2 is a female of Turkish origin with consanguineous
parents. She exhibited neonatal hypertonia and irregular breathing
necessitating continuous positive airway pressure (CPAP) treatment
for several days following birth. In addition, she had episodes of neo-
natal bradycardia and an excessive startle reﬂex, although conscious-
ness was unaltered during startle episodes. She had a short period of
generalized stiffness following the startle response during which vol-
untary movements were impossible. MRI imaging performed at
2 months of age showed bilateral periventricular cystic changes, in
Fig. 1. Human GlyR β subunit mutations identiﬁed in individuals with startle disease/hyperekplexia. Amino acid sequences of the human GlyR α1 and β subunits indicating the
positions of putative membrane-spanning domains (grey shaded boxes) deﬁned by alignments with GluCl (Hibbs and Gouaux, 2011) and amino-acid residues affected by
hyperekplexia mutations. Mutation key: dominant mutation: red; recessive: blue; de novo: orange. Green lettering denotes key ligand-binding residues in the GlyR α1 and β sub-
units. Purple lettering denotes the gephyrin-binding motif between M3 and M4 of the GlyR β subunit.
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She was not dysmorphic and is not currently of small stature, at only
−1 SD below the mean. At 4 months of age she had screaming pe-
riods without a clear loss of consciousness. Concurrently, she had
spasms in the jaw and unusual movements of her arms. At that
time her EEG was normal without focal signs. At 16 months of age
she had an abnormal EEG with clear high-amplitude spike and wave
activity and occasional hypsarrythmia (high amplitude and irregularTable 1
Single nucleotide variants in GLRB associated with startle disease/hyperekplexia. Mutation
2012; Lee et al., 2012; Rees et al., 2002). Panel: DNA sequence electropherograms for the t
study. Bioinformatics analysis was conducted using SIFT (Kumar et al., 2009) with ENSP000
Position Exon Protein precursor/mature Type
c.T596G 6 M199R/M177R Missense
c.G752A 8 G251D/G229D Missense
IVS5+5G>A – – Splice site
c.920_921ΔInsGA 9 L307R/L285R Missense
c.G996T 9 W332C/W310C Missense
c.C1028T 9 S343F/S321F Missensewaves and spikes in a background of chaotic and disorganized activi-
ty). She was treated with nitrazepam and both the seizures and EEG
changes disappeared. She currently takes clonazepam and has no fur-
ther symptoms. She does not have gaze palsy, eye movement disor-
ders, nor any apparent learning difﬁculties. According to the family
her parents and maternal uncle had ‘light symptoms’ in early life.
However, further details of their early childhood have been lost
over time and bound up within cultural restrictions surroundings G229D/IVS5+5G>A, M177R, and S321F were reported previously (Al-Owain et al.,
wo novel mutations (c.920_921ΔInsGA/L285R and c.G996T/p.W310C) reported in this
00264428 and Polyphen-2 (Adzhubei et al., 2010).
SIFT Polyphen-2 Overall prediction
Damaging (0) Possibly damaging (0.802) Pathogenic
Damaging (0) Probably damaging (1.0) Pathogenic
– – Pathogenic
Damaging (0) Probably damaging (0.997) Pathogenic
Damaging (0) Probably damaging (0.999) Pathogenic
Damaging (0) Probably damaging (0.990) Pathogenic
141V.M. James et al. / Neurobiology of Disease 52 (2013) 137–149disclosure. Her older sister (untested) has clear symptoms and her
younger brother born in 2010 (tested) is also affected. The parents
(both heterozygous for W310C) do not currently show any
hyperekplexia symptoms.
Molecular modeling
M177R, L285R and W310C substitutions were predicted (Table 1)
to be damaging or probably/possibly damaging using SIFT (Kumar et
al., 2009) and Polyphen-2 (Adzhubei et al., 2010), respectively. These
bioinformatics tools predict the possible impact of an amino acid sub-
stitution on the structure using the conservation of amino acid resi-
dues in sequence alignments derived from related sequences and
machine learning approaches. To gain further insights into the poten-
tial pathogenic mechanisms of these mutations, we constructed a ho-
mology model of the human α1β GlyR based on the crystal structure
of the GluCl α subunit from C. elegans (Hibbs and Gouaux, 2011). The
GluCl structure makes a signiﬁcantly better template for homology
modeling of the human GlyR compared to other ligand-gated ion
channel structures such as Gloeobacter violaceus GLIC (Bocquet et al.,
2009), Erwinia chrysanthemi ELIC (Hilf and Dutzler, 2009) or the
Torpedo marmorata nAChR (Unwin, 2005) due to functional similarity
(i.e. GluCl is an anion channel) and higher overall sequence identity.
Proﬁle–proﬁle alignment between the human GlyR subunits and
the GluCl α subunit generated using MUSCLE (Edgar, 2004) and
T-COFFEE (Notredame et al., 2000) resulted in 44.4% (α1) and 38.9%
(β) identity. By contrast, GlyR subunits share lower sequence identity
with GLIC (α1: 21.8% and β: 24.6%) and different nAChR subunits
(α1: 19.7 to 20% and β: 23.9 to 24.6%). Our GlyR model (Fig. 2A) pre-
dicts that L285 in the GlyR β subunit is a pore-lining residue,
projecting a small uncharged, hydrophobic side chain into the
ion-channel lumen (Fig. 2B). The L285R mutation introduces a sig-
niﬁcantly larger, positively-charged side chain that projects into the
pore lumen (Fig. 2C). Because this mutation is de novo and the indi-
vidual is heterozygous for L285R, in theory heteromeric GlyRs couldFig. 2.Molecular modeling of the human α1β GlyR and mutation L285R. (A) Side view of the
subunits in blue. The positions of the inner and outer membrane surfaces are indicated by
position of the L285 side chain in the ion-channel pore. (C) Panels depicting the multiple
subunits harboring the L285R substitution. A red plus sign denotes the positive charge carrbe formed in vivo containing 3×wild-type, 1×, 2× or 3× mutant
GlyR β subunits (Fig. 2C). Modeling of pore-lining residues at a
β subunit/β subunit interface (Fig. 3A, B) reveals that L285 is at
the 9′ position in M2, equivalent to L254 in GluCl. This mutation is
predicted to disrupt the pentameric radial symmetry of the 9′ leucine
‘hydrophobic girdle’, that is essential for stabilizing the pore in the
closed channel state. Disruption of this girdle is well known to induce
spontaneous channel activity and/or enhance agonist sensitivity in
other Cys-loop receptors (Chang and Weiss, 1998, 1999). In common
with GluCl, none of the major pore-lining residues are charged, with
the exception of D271 at the -5′ position at the cytoplasmic end of
M2 (Fig. 3A). This is consistent with different models of anion channel
function which suggest that the positive electrostatic potential at the
base of the pore arises from either: i) buried basic residues at the
intracellular entrance of the pore (Cymes and Grosman, 2011), such
as R276 in the M2 0′ position in the GlyR β subunit (R252 in the
GlyR α1 subunit) or ii) oriented peptide dipoles in the M2 α helices
(Hibbs and Gouaux, 2011). Given that the electrostatic potential
at the 0′ position strongly inﬂuences single-channel conductance
(Chang and Weiss, 1998, 1999), it is possible that the introduction
of a large, positively-charged residue at the 9′ position could have a
similar effect.
By contrast, the side-chain of W310 in M3 is part of an
intramembrane network of aromatic residues (phenylalanine, tyrosine,
histidine and tryptophan) contributed by M1, M3 and M4 (Fig. 4A, B).
Substitution W310C introduces a signiﬁcantly smaller and shorter side
chain into this position (Fig. 4C), with a reactive sulfhydryl group. Al-
though we considered that C310 might form a disulﬁde bond with
C314 in M3, one turn down the helix in our model, the distance be-
tween the two sulfur atoms (4.6 Å) precludes this interaction
(Careaga and Falke, 1992). In addition, disulﬁde bonds rarely formwith-
in the membrane or a reducing intracellular environment. Rather, our
modeling predicts that theW310C substitution disrupts aromatic stack-
ing (Fig. 4B) — a key requirement for correct GlyR assembly and
cell-surface trafﬁcking (Haeger et al., 2010).molecular model of the human GlyR α1β pentamer showing α1 subunits in gold and β
grey spheres. (B) Orthographic view of the GlyR α1β pentamer, showing the relative
GlyR isoforms that could be formed on co-expression of wild-type and mutant GlyR β
ied by the side-chain of R285.
Fig. 3.Mutation L285R inserts a charged residue into the GlyR ion-channel pore. (A) Sequence alignment of M2 of GluCl with GlyR α1 and β subunits. Relative positions of residues
that line the Cl− channel are indicated with black circles and residue numbers indicated for GluCl and the GlyR β subunit. Residues carrying presumed positive and negative charges
are colored red and blue, respectively, although it should be noted that the protonation state of these residues at physiological pH has not been established. The position of L285 is
indicated by grey highlighting. (B, C) Schematic diagrams depicting two GlyR β subunit M2 α-helices and residues lining the Cl− channel for wild-type L285 (B) and the R285 mu-
tant (C). Blue spheres represent the predicted internal volume of the ion channel and side-chains are shown for pore-lining residues. The L285R substitution is predicted to create a
premature narrowing of the pore at the 9′ position and inserts a positively charged residue (+) into an α helix that is uncharged, with the exception of D271 on the cytoplasmic face
of the ion-channel pore.
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domain on a β-sheet (β7). The side-chain of this residue forms part of a
hydrophobic pocket (Fig. 5A) that is conserved within the GluCl struc-
ture (Hibbs and Gouaux, 2011), which has an isoleucine at the equiva-
lent position. The M177R substitution results in the introduction of a
positively-charged, hydrophilic side chain into this pocket (Fig. 5B),
which is predicted to have a signiﬁcant effect on the folding of the extra-
cellular domain. Although M177/R177 are not predicted to directly in-
ﬂuence glycine binding (Fig. 5C, D), disruption of the local structure
aroundM177 is predicted to cause an indirect effect on agonist binding
or signal transduction. For example, M177 is located just ﬁve residues
away from F182, which is involved in a cation-π interaction (Pless et
al., 2008) with the amino group of glycine.
Cell-surface biotinylation assays
To establish whether the GlyR β subunit mutants impaired
cell-surface expression of GlyRs, we carried out cell-surface biotinylation
assays for heteromeric α1β GlyRs (Chung et al., 2010), detecting
β-subunit expression using a speciﬁc antibody. Note that in the absenceof theGlyRα1 subunit, the GlyRβ subunit is not expressed at the cell sur-
face in HEK293 cells, but is retained in the rough endoplasmic reticulum
(Kirsch et al., 1995). TheM177R, L285R andW310Cmutant polypeptides
were all detected at equivalent levels to the wild-type GlyR β subunit in
total cell lysates, suggesting that they synthesized correctly and are not
prone to rapid degradation (Fig. 6A). However, quantiﬁcation of the
biotinylation of heteromeric cell-surface α1β GlyRs revealed signiﬁcant
decreases in cell-surface expression of α1βL285R and α1βW310C subunit
GlyRs (Fig. 6A, B) to 27.3±1.1% for L285R and 21.5±8.3% for W310C
of the level of wild-type α1β GlyRs. By contrast, α1βM177R GlyRs had a
similar level of cell-surface expression (104±2.2%) when compared to
wild-type α1β GlyRs.
Functional analysis using EYFP Cl− sensors and electrophysiology
HEK AD293 cells were co-transfected with expression constructs
encoding the GlyR α1 subunit together with each GlyR β subunit mu-
tant. To reproduce the heterozygous state, GlyRα1 was co-transfected
with wild-type and mutant GlyR β subunits. We initially employed
the EYFP assay (Chung et al., 2010; Kruger et al., 2005) to provide
Fig. 4.Mutation W310C disrupts hydrophobic stacking of membrane-spanning domains M1–M3. (A) Cutaway view from the extracellular side of the GlyR β subunit showing how
the side-chain of residue W310 in M3 contributes to a hydrophobic stack of aromatic residues contributed by membrane-spanning domains M1, M3 and M4. Hydrophobic
side-chains of residues predicted to be involved in this stack are colored according to membrane-spanning domain: M1: red; M3: yellow and M4: blue. (B) Mutation W310C results
in the loss of the aromatic, hydrophobic side chain of tryptophan and replacement with the shorter, reactive cysteine sulfydryl side chain. (C–F) Top and side views showing the
hydrophobicity of individual residues in the stack by coloring the atom surfaces. Hydrophobic surfaces are depicted in orange, hydrophilic in blue and white indicates neutral po-
larity. The W310C substitution is predicted to disrupt the hydrophobic stack, altering the tertiary fold of the membrane-spanning domains and introduce an empty space (F, circled
with a dashed line). Disulﬁde bond formation is unlikely, since this is rare within the membrane or an intracellular environment and the only adjacent sulfur atom (C314 in M3) is
6.4 Å away from C310 sulfur.
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The advantage of this approach is that responses of large numbers of
cells can be averaged, thus permitting the reliable quantitation of
small changes in the current ﬂuxing capacity of functional GlyRs. Gly-
cine dose–response relationships (Fig. 7A, B) revealed that themaximal
ﬂuorescence quench was signiﬁcantly reduced for α1βL285R, α1ββL285R,
α1βW310C and α1ββW310C GlyRs relative to wild-type α1β GlyRs
(Fig. 7C), suggesting that mutations L285R and W310C reduce anion
ﬂux rates in both the homozygous and heterozygous states. We also
found that the reduction of Cl- ﬂux was dependent on the ratio of
wild-type GlyR α1 subunit (the amount was held constant) to mutant
GlyR β subunits (Fig. 7D), with signiﬁcantly reduced Cl- ﬂux observed
with increasing levels of βW310C expression. Given that α1β GlyRs
exist in an invariant 2α:3β stoichiometry (Yang et al., 2012), weinfer that increasing the βW310C:α1 subunit ratio increases the propor-
tion of heteromeric GlyRs, which in turn reduces functional GlyR ex-
pression. These data are consistent with our biotinylation assays, and
suggest βW310C subunits prevent wild-type GlyR subunits from trafﬁck-
ing to the cell surface. EC50 values for wild-type α1β, α1βL285R and
α1βW310C GlyRs were 5±1, 4±1, 13±2 μM, respectively (Table 2),
suggesting that the L285R and W310C mutations do not substantially
alter the agonist sensitivity of recombinant α1β GlyRs reaching the
cell surface.
To test if the mutated β subunits incorporate into functional GlyRs,
the pore blocker lindane was applied. Lindane potently inhibits
homomeric α subunit GlyRs, but has almost no effect on heteromeric
αβ subunit GlyRs (Islam and Lynch, 2012). GlyRs containing βL285R or
βW310C subunits exhibited a reduced sensitivity to lindane, indicating
Fig. 5.Mutation M177R disrupts local structure of a β-sheet in the N-terminal extracellular domain. (A, B) Side views of part of the GlyR β subunit extracellular domain showing the
location of M177 (A) and R177 (B, red lettering) within a β-sheet structure. The polarity of the surface residues is shown with hydrophobic residues depicted in orange, hydrophilic
in blue and white indicating neutral polarity. (C) Rotating the model 180° horizontally shows that M177 is located close to F182, which is involved in a cation-π interaction with the
amino group of glycine. (D) Top view of M177, relative to the ligand-binding domain, rotated 90° vertically from B. Thus, mutation M177R is predicted to result in the loss of a
hydrophobic side-chain and replacement with a positively-charged side chain. This substitution is predicted to disturb the local fold of the extracellular domain and have a
knock-on effect for positioning of the critical ligand-binding residue F182.
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expressed at the cell surface (Fig. 7E). Since artiﬁcial mutations at the
9′ position in GABAC and GABAAR subunits result in spontaneously-
opening channels (Chang andWeiss, 1998, 1999), we also investigated
whether α1βL285R GlyRs showed this property, by quantifying the ﬂuo-
rescence change in the absence of glycine. Bothα1βL285R andα1ββL285R
GlyRs showed a signiﬁcant increase in quench relative to heteromeric
α1β GlyRs, which is suggestive of spontaneous activity (Fig. 7F). Even
in the absence of glycine, the quench observed was >20%. By contrast,
the quench observed in the absence of glycine for α1βW310C containing
GlyRs was only slightly higher than for wild-type GlyRs, suggesting that
these GlyRs do not show spontaneous gating. Averaged results obtained
using the EYFP Cl− ﬂux assay for L285R andW310C are summarized in
Table 2.
Electrophysiology was subsequently used to analyze the effects of
the L285R and W310C mutations on GlyR function in greater detail.
Dose–response relationships conﬁrmed that the agonist sensitivity for
GlyRs containing either mutated subunit did not change relative to
wild-type α1β heteromers (Fig. 8A, B). As in the EYFP assays, the pres-
ence of the GlyR β subunit was conﬁrmed by applying lindane
(Fig. 8A). Spontaneous activity of α1βL285R-containing GlyRs could be
inhibited by the pore-blocker picrotoxin (Fig. 8C). However, due to
the resistance of heteromeric α1β GlyRs to picrotoxin (Pribilla et al.,
1994), this inhibition was typically only about 100 pA. Single-channel
recordings in the absence of glycine conﬁrmed the spontaneous activity
of α1βL285R GlyRs (Fig. 8D). Averaged over four patches, mean open
probability in the absence of applied glycine was 0.04±0.01. Themaximal unitary conductance level (denoted by γ2 in Fig. 8D) was
49.4±0.7 pS with an additional sub-conductance level (γ1) at 23.9±
0.3 pS (both n=4 patches). The dominant 49 pS level corresponds
closely to that observed in wild-type α1β GlyRs (44 pS) (Bormann et
al., 1993), indicating that the L285R substitution does not affect
single-channel conductance. To investigate the properties of α1βW310C
GlyRs, whole-cell recordings were made from >200 EGFP-expressing
cells that had been transfected with both α1 and βW310C subunits in a
1:10 molar ratio. Only 20 of these cells expressed glycine-gated cur-
rents, with only two of the 20 expressing lindane-insensitive GlyRs,
suggesting a predominance of α1βW310C GlyRs in the cell membrane.
In both of these cells, the maximal current amplitude was signiﬁcantly
reduced relative to wild-type GlyRs (Fig. 8E), suggesting a reduction
in either maximum open probability, single-channel conductance,
and/or the number of functional channels expressed in the plasma
membrane. Based on the biotinylation results, we can conclude that
the reduced current amplitude is at least partly caused by reduced
cell-surface expression. The properties of whole-cell currents mediated
by α1βL285R and α1βW310C GlyRs are summarized in Table 3.
The M177R mutant resulted in both a reduction of maximal ﬂuo-
rescence quench (Fig. 9A, B) and a rightward shift in the EC50 value
for glycine (Fig. 9A) from 17±5 μM for wild-type α1β GlyRs to
45±14 μM α1ββM177R and 64±13 μM for α1βM177R GlyRs
(Table 4). Heteromeric α1βM177R GlyRs exhibited a slightly reduced
sensitivity to lindane (Fig. 9C). However, the reduced glycine sensitivity
indicates that receptors incorporating the βM177R subunit are expressed
at the cell surface. Using patch-clamp electrophysiology, we conﬁrmed
Fig. 6. Cell-surface biotinylation assays for GlyR β subunit mutations. (A) Cell-surface
biotinylation assays on heteromeric α1β GlyRs expressed in HEK293 cells revealed that
all three GlyR β subunit mutants (M177R, L285R and W310C) were expressed at similar
levels in whole-cell protein expression (total) compared to an actin control. However,
mutations L285R and W310C revealed markedly reduced cell-surface protein expression
(surface) compared to wild-type or the M177R mutant. 70 μg of protein lysates were
loaded in the each lane. (B) Quantiﬁcation of cell surface and whole cell expression of
the GlyR β subunit mutants using ImageJ software, with values expressed as a percentage
of wild-type GlyR β subunit expression. p-Values were calculated relative to wild-type
GlyR β expression using an unpaired t-test; ***=pb0.001.
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39±4 μM for wild-type α1β GlyRs to 162±3 μM for α1βM177R GlyRs
(Fig. 9D, E) and that peak current magnitudes relative to wild-type
α1β heteromers were signiﬁcantly reduced (Fig. 9D, E, Table 3). We
infer from these results that βM177R was incorporated efﬁciently into
functional heteromeric GlyRs. However, incorporation of βM177R did
not render GlyRs completely insensitive to lindane (Fig. 9E, inset).Discussion
This study reports the identiﬁcation and functional characterization
of novel mutations in the GlyR β subunit gene (GLRB) that reveal
new pathogenic mechanisms underlying startle disease/hyperekplexia.
We identiﬁed two new missense variants in GLRB causing L285R and
W310C substitutions in membrane spanning domains M2 and M3.
Using molecular modeling, cell-surface biotinylation assays, an EYFP-
based anion ﬂux assay and patch clamp electrophysiology, we were
able to establish the likely pathogenic mechanisms for L285R and
W310C, as well as a third mutation – M177R – recently reported
(Al-Owain et al., 2012) in a large Saudi Arabian family with
hyperekplexia. L285R is a de novomutation, i.e. not found in either par-
ent, which reduces peak currentmagnitude by reducing the cell-surface
trafﬁcking of GlyRs. Since the L285R substitution disrupts the integrity
of the 9′ leucine hydrophobic girdle that stabilizes the channel closed
state (Chang and Weiss, 1998, 1999), it was perhaps inevitable that
α1βL285R GlyRs were also associated with leak conductance indicatingtonic channel opening. Since we recently described a dominant GlyR
α1 subunit mutation in the large extracellular domain (Y128C) with a
leak conductance (Chung et al., 2010), this pathogenic mechanism is
an emerging theme in startle disease. Introduction of the pore-lining
9′ arginine residues might also have been expected to affect unitary
conductance (Cymes and Grosman, 2011). However, we found that
the dominant maximum conductance level of α1βL285R GlyRs (49 pS)
was similar to that of α1β GlyRs (44 pS) (Bormann et al., 1993).
On ﬁrst impressions, W310C also appeared to be a classical reces-
sive hyperekplexia mutation, interfering with the formation of
cell-surface GlyRs, rather than affecting glycine sensitivity. However,
detailed analysis revealed both novel pathogenic mechanisms and
mode of inheritance for this missense mutation. Molecular modeling
revealed that W310 is a key residue involved in a hydrophobic stack
formed by aromatic residues in M1, M3 and M4 that determines
GlyR subunit stoichiometry (Haeger et al., 2010). The W310C substi-
tution in M3 is predicted to act by destabilizing intramembrane pack-
ing of α-helices, a result that is in accord with our functional studies,
which show compromised cell-surface expression of α1βW310C and
α1ββW310C GlyRs and the formation of a signiﬁcant proportion of
GlyR α1 subunit homomers even in the presence of a ten-fold excess
of βW310C. However, we cannot rule out the possibility that reductions
in channel open probability or single-channel conductance may also
have contributed to the reduced current-carrying capacity of these
mutant receptors. The inheritance of this mutation is of signiﬁcant
clinical interest, since mild startle symptoms were reported in both
parents. This mutation is likely to represent a case of incomplete
dominance, i.e. a mutation that has an intermediate effect in hetero-
zygous carriers. This mechanism is supported by our functional
data, since the maximal quench was signiﬁcantly reduced for both
α1βW310C and α1ββW310C GlyRs compared to wild-type α1β GlyRs.
It is tempting to speculate that mutations such as W310C in GLRB
might form the genetic basis for ‘minor startle’, an excessive startle
response in the absence of hypertonia. This phenomenon has been
reported (Tijssen et al., 1995, 1996, 2002) in several hyperekplexia
studies, but even though ‘major’ and ‘minor’ startle can occur togeth-
er in the same family, the genetic basis remains unresolved and it has
been assumed by some to be a ‘normal but pronounced startle re-
sponse’. Our study suggests that certain GlyR mutations may show in-
complete dominance, providing a potential genetic explanation for
mild startle in heterozygous carriers. This mild startle is predicted
to be more common for GLRBmutations, since the likelihood of a het-
erozygous carrier being able to synthesize fully wild-type GlyRs with
a 2α1:3β stoichiometry when carrying a defective GLRA1 allele is 1 in
4, versus 1 in 8 for a defective GLRB allele.
The remaining GLRB substitution we studied in detail was M177R,
which both molecular modeling and functional studies suggest does
not disrupt cell-surface trafﬁcking, but interferes indirectly with ago-
nist binding, by disrupting a local β-sheet fold in the large extracellu-
lar domain. M177 is located just ﬁve residues away from F182, which
participates in a cation-π interaction with glycine (Pless et al., 2008).
Thus, the pathogenic mechanism for M177R resembles that of a pre-
viously reported mutation G229D, which also displayed a reduced
EC50 for glycine (Rees et al., 2002).
Our ongoing genetic screening program has recently revealed nu-
merous recessive mutations in the genes encoding the GlyR α1
subunit (GLRA1) and GlyT2 gene (SLC6A5). However, one conundrum
is why so few GLRB mutations have been reported in startle disease.
In part, this may be historical: GLRA1 was the ﬁrst startle disease
gene to be discovered in 1993 (Shiang et al., 1993) and mutations
in this gene explain the majority of cases of dominant hyperekplexia.
By contrast, mutations in GLRB and SLC6A5were ﬁrst reported in 2002
and 2006, respectively (Rees et al., 2002, 2006). This ‘head start’ for
GLRA1 is reﬂected in the NCBI gene-testing registry. Of the clinical
laboratories world-wide offering screening for startle disease, seven
screen for GLRA1 mutations, three offer screening for GLRB and only
Fig. 7. Functional characterization of human GlyR βL285R and βW310C mutations using the EYFP assay. (A, B) Mean glycine dose–response curves for α1, α1β, α1βL285R, α1ββL285R,
α1βW310C andα1ββW310C GlyRs. The percentage quench is plotted against the applied glycine concentration (μM). Averaged parameters of best ﬁt to dose–response curves are sum-
marized in Table 2. (C) Maximal changes in ﬂuorescence.ΔFmax is the initial ﬂuorescence valueminus the ﬁnal ﬂuorescence value and is represented in ﬂuorescence units. p-Valueswere
calculated relative toα1β GlyR heteromers by unpaired t-test: * pb0.05, ** pb0.01, *** pb0.001. (D)Maximal changes in ﬂuorescence for GlyR subunits transfected in differentα:β ratios
while the amount of α1 transfected was held constant. * pb0.05 by unpaired t-test. (E) Inhibition by 100 μM lindane. The inhibition of currents activated by 10 μM glycine by 100 μM
lindane is represented as a percentage reduction of the control maximal ﬂuorescent quench. p-Values were calculated relative to GlyR α1 homomers by unpaired t-test: * pb0.05,
** pb0.01, *** pb0.001. (F) Fluorescent quench in the presence of sodium iodide (no glycine). p-Values were calculated relative to GlyR α1β heteromers by unpaired t-test: * pb0.05,
** pb0.01, *** pb0.001. All data points displayed in this ﬁgure represent the average quench from four experiments comprising three wells each with>200 cells per well.
Table 2
Properties of human GlyRs containing βL285R and βW310C subunits using the EYFP assay.
EC50 values, Hill coefﬁcients (nH), the maximal ﬂuorescence changes (ΔFmax), the max-
imal percentages of quenched cells (cellsquench) and the inhibition of 10 μM glycine
currents by 100 μM lindane (LINinh) are represented. p-Values were calculated relative
to GlyR α1β subunit heteromers except for inhibition by lindane, which was compared
to GlyR α1 subunit homomers by unpaired t-test.
EYFP assay
EC50 (μM) nH ΔFmax (FU) cellsquench (%) LINinh (%) n
α1 8±1 1.7±0.1 44±1 94±2 111±4 12
α1β 5±1 3.9±2.2 44±2 96±2 38±2⁎⁎⁎ 12
α1βL285R 4±1 0.9±0.1⁎ 19±2⁎⁎⁎ 86±7 6±7⁎⁎⁎ 12
α1ββL285R 4±1 0.9±0.1⁎ 19±2⁎⁎⁎ 83±5 14±7⁎⁎⁎ 12
α1βW310C 13±2⁎ 4.3±1.8 32±3⁎ 81±5⁎ 51±10⁎⁎ 12
α1ββW310C 11±1⁎⁎ 5.1±1.5 32±1⁎⁎ 90±1⁎ 32±12⁎⁎⁎ 12
⁎ pb0.05.
⁎⁎ pb0.01.
⁎⁎⁎ pb0.001.
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not reﬂect the true prevalence of disease alleles— for example, we re-
cently reported twenty new pathogenic sequence variants for GlyT2
in 17 index cases (Carta et al., 2012), as well as a new dominant
GlyT2 mutation found in multiple families (Giménez et al., 2012).
These studies certainly suggest that SLC6A5 is a major startle disease
gene. Methodology may also play a role: initial attempts at screening
GLRB used single-strand conformation polymorphism (SSCP) or
bi-directional di-deoxy ﬁngerprinting (ddF) methods (Milani et al.,
1998; Rees et al., 2002), which have variable sensitivity for mutation
detection. By contrast, our study and two other recent reports
(Al-Owain et al., 2012; Lee et al., 2012) have used Sanger DNA
sequencing – currently the method of choice for mutation detection –
although this is likely to be superseded in time by targeted next-
generation sequencing panels (Lemke et al., 2012). The extended clini-
cal phenotype in these cases, encompassing breathing difﬁculties/
severe neonatal apnea episodes, bradycardia and developmental
delay is likely to be explained by the loss of multiple synaptic GlyR
Fig. 8. Functional characterization of human GlyRs containing βL285R and βW310C using electrophysiology. (A) Sample glycine dose–response traces of α1β, α1βL285R and α1βW310C
GlyRs. Filled bars indicate the applied glycine concentrations in μM and non-ﬁlled bars the application of 100 μM lindane. The effect of 100 μM lindane on homomeric α1 subunit
GlyRs is included as a control. (B) Normalized glycine dose–response curves for the GlyRs shown in panel A. (C) Inhibition of leak currents in α1βL285R GlyRs by 100 μM picrotoxin
(PTX). The inward current transient was always observed (n=5 cells). (D) Spontaneous single-channel currents for α1βL285R GlyRs. Most openings were of 2–10 ms duration as
illustrated in Patch 1. Occasionally, with multiple channels in the patch, longer activations were also observed, as in Patch 2. (E) Mean currents activated by 100 μM glycine in
cells expressing α1β GlyRs in a 1:1 ratio relative to those in cells expressing α1βW310C GlyRs in a 1:10 ratio. p-Values were calculated relative to GlyR α1β heteromers by unpaired
t-test: ** pb0.01.
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In this regard, it is noteworthy that GlyR α3 subunit knockout mice
were recently shown to have an irregular respiratory rhythm, due to
loss of 5HT1A-mediated modulation of GlyRs in the brainstem
(Manzke et al., 2010).
It is also clear that there are key differences in the relative damage
caused by equivalent missense changes in GlyR α1 versus GlyR β sub-
units. For example, dominant startle disease mutations in GLRA1 pre-
dominantly affect key amino acid residues in the M2 domain and
M2-M3 linker region of the GlyR α1 subunit (Fig. 1A), where they actTable 3
Properties of α1β, α1βL285R, α1βW310C and βM177R GlyRs using whole-cell patch-clamp
electrophysiology. EC50 values, Hill coefﬁcients (nH) and the maximal currents (Imax)
are represented. p-Values were calculated relative to the wild-type α1β subunit
GlyRs by unpaired t-test.
Whole-cell patch-clamp electrophysiology
EC50 (μM) nH Imax (nA) n
α1β 39±4 2.4±0.2 14±3 5
α1βL285R 49±7 1.2±0.1⁎⁎ 9±4 3
α1βW310C 28, 58 1.7, 4.0 0.22, 0.15 2
α1βM177R 162±3⁎⁎⁎ 2.2±0.1 8±1 5
⁎⁎ pb0.01.
⁎⁎⁎ pb0.001.to uncouple ligand-binding from channel gating. Shan et al. (2011) re-
cently demonstrated that GlyR function is less sensitive to
hyperekplexia-mimicking mutations introduced into the M2–M3 loop
of the GlyR β subunit than the α1 subunit. This suggests that the GlyR
α1 M2–M3 loop dominates the β subunit in gating heteromeric α1β
GlyRs and in turn that it is perhaps unlikely that a set of equivalent dom-
inant mutations in the M2–M3 linker (Fig. 1A) will be found in GLRB.
This is consistent with our ﬁnding that GlyRs containing the L285Rmu-
tant exhibit an EC50 that is similar to wild-type, conﬁrming that the β
subunit is not the major mediator of signal transduction in heteromeric
GlyRs. Rather, the GLRBmutations found to date appear to cluster near
key glycine binding residues (M177R, G229D) or are found in
membrane-spanning domainsM1–M3 (Fig. 1B), where they disrupt re-
ceptor trafﬁcking and affect ion-channel function (L285R) or hydropho-
bic side-chain stacking (W310C).
Other potential pathogenic mechanisms for GLRB include protein
truncation (via deletion, frameshift, splice site or nonsense muta-
tions) or mutations in the gephyrin-binding site located between
M3 and M4 (Fig. 1B). At least in vitro, artiﬁcial missense mutations af-
fecting single amino acids, such as F398A in the GlyR β subunit
gephyrin-binding motif are capable of signiﬁcantly impairing GlyR
β-gephyrin interactions (Kim et al., 2006), which would in turn abol-
ish GlyR clustering at synapses. Based on our previous experience
with GLRA1 and SLC6A5, we consider it likely that a number of reces-
sive SNVs remain to be discovered in GLRB. Based on the discovery of
four new GLRB variants associated with hyperekplexia in this year
Fig. 9. Functional characterization of human GlyRs containing βM177R using the EYFP assay and electrophysiology. (A) Mean glycine dose–response curves for α1, α1β, α1βM177R and
α1ββM177R GlyRs using the EYFP assay. The percentage quench is plotted against the applied glycine concentration (μM). Averaged parameters of best ﬁt to dose–response curves
are summarized in Table 3. All data points represent the average quench from four experiments comprising three wells each with>200 cells per well. (B) Maximal changes in ﬂuo-
rescence. ΔFmax is the initial ﬂuorescence value minus the ﬁnal ﬂuorescence value and is represented in ﬂuorescence units. p-Values were calculated relative to α1β GlyR
heteromers by unpaired t-test: * pb0.05, *** pb0.001. (C) Inhibition by 100 μM lindane. The inhibition of currents activated by 100 μM glycine by 100 μM lindane is represented
as a percentage reduction of the control maximal ﬂuorescent quench. p-Values were calculated relative to GlyR α1 homomers by unpaired t-test: ** pb0.01, *** pb0.001. (D) Nor-
malized glycine dose–response results using whole-cell patch-clamp electrophysiology for the GlyRs shown in panel E. The normalized maximal currents of cells transfected with
the indicated plasmid vectors are plotted against the applied glycine concentration (μM). (E) Sample glycine dose–response traces. Filled bars indicate the applied glycine concen-
tration in μM and non-ﬁlled bars the application of 100 μM lindane.
148 V.M. James et al. / Neurobiology of Disease 52 (2013) 137–149alone (Al-Owain et al., 2012; Lee et al., 2012, this study), we recom-
mend that GLRB should have equal status alongside GLRA1 and
SLC6A5 in the molecular genetic diagnosis of startle disease.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.nbd.2012.12.001.Table 4
Properties of α1βM177R GlyRs using the EYFP assay. EC50 values, Hill coefﬁcients (nH),
the maximal ﬂuorescence changes (ΔFmax), the maximal percentages of quenched
cells (cellsquench) and the inhibition of 100 μM glycine currents by blocking with
100 μM lindane (LINinh) are represented. p-Values were calculated relative to GlyR
α1β subunit heteromers except for inhibition by lindane, which was compared to
GlyR α1 subunit homomers by unpaired t-test.
EYFP assay
EC50 (μM) nH ΔFmax (FU) cellsquench (%) LINinh (%) n
α1 25±5 1.5±0.1 46±2 97±1 92±5 12
α1β 17±5 1.7±0.1 50±1 96±1 42±6⁎⁎⁎ 12
α1βM177R 64±13⁎ 3.4±1.9 29±1⁎⁎⁎ 81±2⁎⁎⁎ 54±8⁎ 12
α1ββM177R 45±14 3.4±1.9 31±2⁎ 84±2⁎⁎⁎ 60±7⁎⁎ 12
⁎ pb0.05.
⁎⁎ pb0.01.
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